Showing 3661-3670 of 4063 results for "".
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluidhttps://modernod.com/news/new-phase-3-analysis-demonstrates-beovu-showed-improvement-in-bcva-in-wet-amd-patients-with-early-persistent-fluid/2478364/Novartis announced that results of two new post-hoc analyses of the phase 3 HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the Euretina 2020 virtual congress. The first analysis demonstrated fewer Beovu (brolucizumab) patients had early per
- Centricity Vision Appoints Jim Mazzo to its Board of Directorshttps://modernod.com/news/centricity-vision-appoints-jim-mazzo-to-its-board-of-directors/2478353/Centricity Vision announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mr. Mazzo has over 40 years of experience in the ophthalmology industry. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- Employers Will Need to Respond Carefully Amid Roller Coaster of Health Costs During COVID-19https://modernod.com/news/employers-will-need-to-respond-carefully-amid-roller-coaster-of-health-costs-during-covid-19/2478345/Employers will likely see drops in year-over-year medical costs in 2020 after large numbers of employees deferred healthcare services due to the COVID-19 pandemic, according to a FierceHealthcare report. Despite the significant drop in the use of healthcare services in 2020, employer heal
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- US Eye Network Expands into Southeastern US through Partnership with Carolina Eyecare Physicianshttps://modernod.com/news/us-eye-network-expands-into-southeastern-us-through-partnership-with-carolina-eyecare-physicians/2478319/Carolina Eyecare Physicians has joined the expanding US Eye network. With the addition of Carolina Eyecare Physicians, US Eye, a physician-led network of practices, will operate 24 clinics and 3 surgery centers. <
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in
- Lumenis Unveils Its First US Tour With Launch Of Mobile Outdoor Tradeshow Boothhttps://modernod.com/news/lumenis-unveils-its-first-us-tour-with-launch-of-mobile-outdoor-tradeshow-booth/2478311/Lumenis has announced its first mobile tour (LuMobile), September 28 through April 2021. The company will bring its flagship devices to practitioners in a safe environment aboard the new LuMobile outdoor tradeshow exhibit. The 20-city mo